GC
KPTI icon

GFG Capital’s Karyopharm Therapeutics KPTI Stock Holding History

GFG Capital’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,760
Closed -$226K – 131
2022
Q3 		$226K Hold
2,760
– – 0.07% 114
2022
Q2 		$187K Hold
2,760
– – 0.06% 124
2022
Q1 		$305K Hold
2,760
– – 0.09% 111
2021
Q4 		$266K Sell
2,760
-783
-22% -$78K 0.08% 117
2021
Q3 		$309K Buy
+3,543
New +$368K 0.1% 93

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GFG Capital's KPTI Position: Q4 2022 in Review

GFG Capital sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 2,760 shares — an estimated $226K sold.

GFG Capital first reported a position in KPTI in Q3 2021 and held it in 5 quarters. The position peaked at $309K in Q3 2021. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • GFG Capital reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • GFG Capital sold 2,760 Karyopharm Therapeutics shares in Q4 2022, an estimated $226K.
  • GFG Capital first reported a position in Karyopharm Therapeutics in Q3 2021 and held it in 5 quarters.
  • GFG Capital's Karyopharm Therapeutics position peaked at $309K in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on GFG Capital's 13F filing for Q4 2022, filed 14 Feb 2023.